NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-CA-21-057 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) solicits applications for Connecting Underrepresented Populations to Clinical Trials (CUSP2CT), a program that will implement and evaluate multilevel and culturally tailored outreach and education interventions with the primary goal of increasing referral and ultimately, accrual of underrepresented racial/ethnic (R/E) minority populations, to NCI-supported clinical trials (CTs) (National Clinical Trial Network (NCTN), NCI's Community Oncology Research Program (NCORP), and Experimental Therapeutics Clinical Trials Network (ETCTN)). The target population(s) should include individuals from underrepresented racial/ethnic (R/E) minority populations. Applicants should address cancer health disparities (CHD) through a network of local multidisciplinary and integrated partners that include community health educators (CHEs), lay health advisors (LHAs), community members, healthcare providers, and researchers working in coordination to educate and refer R/E minority populations to NCI-supported CTs, and increase awareness in providers about R/E minority participation in NCI clinical trials. This will require outreach and education multilevel interventions at the CT site, provider, and/or patient levels. The proposed interventions should be informed by relevant theories, frameworks, or models and guided by preliminary data and/or the sufficient infrastructure in place and expertise on the local contextual barriers and facilitators for increasing CT referral of R/E minority population. It is expected that U01 grantees will establish partnerships with the community, primary care providers, and other stakeholders to enhance identification of R/E minority referral barriers and facilitators to NCI-supported CTs. A companion funding opportunity (see U24 funding opportunity RFA-CA-21-058) will support a Data, Evaluation and Coordinating Center (DECC) that will provide experienced project
Funding Opportunity RFA-CA-21-058 from the NIH Guide for Grants and Contracts. The purpose of this solicitation is to fund a Data, Evaluation and Coordinating Center (DECC) that will support the data and evaluation activities and coordinate a learning collaborative related to the CUSP2CT program (companion RFA CA-21-057).
Funding Opportunity RFA-AA-21-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U54 applications for the planning and implementation of collaborative partnerships between Research Centers in Minority Institutions (RCMI) and institutions with extensive alcohol research programs, including NIAAA-funded alcohol research centers and consortia (ARC). RCMI are institutions that offer doctorate degrees in the health professions or in a health-related science and have a historical and current commitment to educating underrepresented students, and for institutions that deliver health care services, providing clinical services to medically underserved communities. ARC refers to institutions with extensive alcohol research programs including, but not limited to, NIAAA-funded alcohol research centers. The long-range goal of the collaborative partnership program between RCMI and ARC is to strengthen the alcohol research capacity, develop research expertise in biomedical and clinical fields to identify, characterize, and reduce adverse health effects due to alcohol use and misuse. This FOA aims to support RCMI to build alcohol research infrastructure and capacity and to enhance diversity in the biomedical workforce.
Funding Opportunity RFA-DK-21-022 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was established in July 2002 for the purpose of identifying genetic variation predisposing to Inflammatory Bowel Disease (IBD). Since its establishment and in collaboration with the International IBD Genetics Consortium, the NIDDK IBDGC has identified over 250 IBD susceptibility loci. However, for the great majority of these loci, the specific causal variants and effector genes have not yet been identified, and the biological mechanisms through which these variants influence IBD pathophysiology remain to be elucidated. The purpose of this FOA is to renew the IBDGC with a continued mission to characterize the genetic architecture of IBD and its sub-phenotypes, particularly in populations currently under-represented in IBD genomic studies, and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology, phenotypes and outcomes, with the long-term goal of improving disease course prediction and treatment. The Genetic Research Centers (GRCs) of the IBDGC will serve as sites for enrollment of IBD patients, relatives and healthy controls, for laboratory-based studies on biological samples taken from these subjects, and for mechanistic studies of the variants identified and of the genes, proteins and pathways they impact. The Program Directors / Principal Investigators of the GRCs will serve as voting members of the Steering Committee of the IBDGC, which will be responsible for all operational decisions, which will be binding upon all members of the IBDGC.
Notice NOT-MH-21-310 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-077 from the NIH Guide for Grants and Contracts
Notice NOT-OH-21-014 from the NIH Guide for Grants and Contracts
Notice NOT-OH-21-013 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HG-21-036 from the NIH Guide for Grants and Contracts. The purpose of the Knockout Mouse Phenotyping Project (KOMP2) is to produce a comprehensive resource of null-mutant mice, and associated phenotype data, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. This Funding Opportunity Announcement (FOA) solicits applications for production and phenotyping centers that will make maximum progress toward completion of KOMP2 in a final five-year project period. The specific objectives are to generate approximately 1,200 mutant mouse lines using CRISPR/Cas9 technology, perform a series of phenotyping assays, cryopreserve germplasm, and make mice and data readily available to the research community. This is a limited competition RFA. Only recipient organizations funded under (RFA-RM-15-017) are eligible to apply.
Funding Opportunity RFA-HG-21-037 from the NIH Guide for Grants and Contracts. The purpose of the Knockout Mouse Phenotyping Project (KOMP2) is to produce a comprehensive resource of null-mutant mice, and associated phenotype data, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. The goal of this FOA is to provide informatics support to NIH funded projects that are performing high-throughput broad-based phenotyping of mouse knock-out (KO) lines (see RFA-HG-21-036) and to coordinate with international efforts so as to integrate all data into a common database under the auspices of the International Mouse Phenotyping Consortium (IMPC). The Data Coordination Center and Database (DCCDB) will perform the validation, analysis, annotation, visualization, and dissemination of the phenotype data from the knockout lines. Curation will require integration with other data sources. This is a limited competition RFA. Only recipient organizations funded under (RFA-RM-15-016) are eligible to apply.
Funding Opportunity RFA-DK-21-019 from the NIH Guide for Grants and Contracts. The purpose of the Development Of Physician Scientists in Diabetes research (Diabetes-DOCS) Program is to support the career development of physicians committed to a career in diabetes research. The Diabetes-DOCS program is intended to remedy the dearth of pediatric endocrinologists and physicians from other specialties conducting outstanding, innovative research into the causes and consequences of diabetes. Diabetes-DOCS will be a single national program, implemented by one or more PD/PIs, together with an advisory committee composed of basic and clinical investigators who have a strong record of funded research and successful training of physician-scientists. Although there will be one national administrative center awardee, scholars are expected to be appointed and supported at their home institutions around the country. The program will start with a focus on Type 1 Diabetes (T1D) research, with funding from the Statutory Special Diabetes Program https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program . Applicants should also plan for a possible expansion (based on competitive review) to support the career development of physicians whose research focuses on NIDDK emphasis areas in type 2 diabetes. The program is expected to deliver on goals to increase the diversity of physician scientists with independent research careers in the mission of NIDDK https://www.niddk.nih.gov/research-funding/research-programs#diabetes.
Funding Opportunity RFA-NS-22-016 from the NIH Guide for Grants and Contracts. More than 25 million Americans suffer from daily chronic pain, a highly debilitating medical condition that is complex and difficult to manage. In recent decades, there has been an overreliance in the prescription of opioids for chronic pain despite their poor ability to improve function and high addiction liability. This contributed to a significant and alarming epidemic of opioid overdose deaths and addictions. Innovative scientific solutions to develop alternative pain treatment options are thus critically needed. Through targeted research efforts, the NIH HEAL Initiative aims to support the development of safe and effective devices to treat pain with little or no addiction liability. This funding opportunity announcement (FOA) is designed to support interdisciplinary research teams of multiple PD/PIs to investigate the mechanism of action of device-based pain relief with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. Program teams are expected to accomplish goals that require considerable synergy and collaborative interactions. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Teams are encouraged to consider objectives that will produce major advances in the field of device-based pain relief.
Funding Opportunity PAR-21-297 from the NIH Guide for Grants and Contracts. The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods) in adolescent and young women. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies. It also encourages biobehavioral and behavioral/social studies to identify MPT end user preferences factors (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT use in adolescent and young women.
Funding Opportunity PAR-21-298 from the NIH Guide for Grants and Contracts. The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods) in adolescent and young women. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies. It also encourages biobehavioral and behavioral/social studies to identify MPT end user preferences factors (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT use in adolescent and young women.
Funding Opportunity RFA-DK-21-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for the Pediatric Centers of Excellence in Nephrology (PCEN) to support basic, translational and clinical research in pediatric kidney disease. The goals of this program are: 1. to attract new scientific expertise to the study of human pediatric renal physiology, kidney development, and pediatric kidney disorders; 2. to encourage multidisciplinary research in these areas; and 3. to develop the pediatric nephrology research community through a national Pilot and Feasibility grant program leading to innovative approaches to study kidney disease in children and the eventual submission of substantial, competitive, investigatorinitiated research applications. The PCEN will complement the OBrien Kidney and Urological Research Centers and are expected to leverage existing institutional resources which may include Clinical Translational Science Awards, Institutional Network Awards for Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1), and other NIDDK-Division of Kidney, Urologic and Hematologic Diseases (KUH)-funded consortia.
Funding Opportunity PAR-21-295 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity of thought in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA.
NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required)
Funding Opportunity PAR-21-296 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity of thought in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA
Funding Opportunity RFA-CA-21-054 from the NIH Guide for Grants and Contracts. The TBEL program aims to integrate basic and translational cancer research concepts to examine the direct causal relationships and interactions of an early lesion, its microenvironment and host-systemic factors as co-organizers of tumor initiation (or suppression) and malignant progression. The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches. The FOA will utilize the U54 (Specialized Center--Cooperative Agreements) activity code. Each TBEL Center shall have a unique thematic focus and be structured to test hypotheses that bridge basic and translational research in a synergistic and iterative fashion. Collectively, TBEL Centers will operate as a network that will inform future, rationally-design modes of intervention that are founded on strong biological mechanisms and be comprehensive, multi-dimensional, and appropriately tailored to the degree of malignant potential of an early lesion.
Funding Opportunity RFA-CA-21-055 from the NIH Guide for Grants and Contracts. The TBEL program aims to integrate basic and translational cancer research concepts to examine the direct causal relationships and interactions of an early lesion, its microenvironment, and host-systemic factors as co-organizers of tumor initiation (or suppression) and malignant progression. The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches. The responsibilities of the CDMC will be to (1) coordinate consortium-wide meetings and conferences, and cross-consortium collaborative activities; (2) provide statistical and computational analysis support; and (3) establish program data hub for data capture, curation and management, and protocol development and registration. The other scientific unit of the TBEL program will comprise the U54 Centers, which will be structured to efficiently bridge gaps between basic and translational research on early lesions and their microenvironments. This Notice is being provided to allow potential applicants sufficient time to develop a responsive TBEL Coordinating and Data Management Center application. The FOA is expected to be published in May 2021 with an anticipated application due date in October 2021. Details of the planned pre-application webinar will be announced in the Guide after publication of the FOA. The companion notice for the TBEL U54 Centers is: NOT-CA-21-XXX. The FOA will not be restricted to specific early lesion/cancer type(s).
Notice NOT-HL-21-029 from the NIH Guide for Grants and Contracts